TABLE 1.
Baseline characteristics of HIV-negative individuals with disseminated cryptococcosis by positivity of serum cryptococcal antigen testing 2002 to 2019 (n = 96)
| Variablea | Positive serum CrAg (n = 76) | Negative serum CrAg (n = 20) | P value |
|---|---|---|---|
| No. male (%) | 52 (68) | 12 (60) | 0.477 |
| Age in years (median, IQR) | 58 (49, 68) | 54 (42, 63) | 0.144 |
| No. African American (%) | 8 (11) | 3 (15) | 0.758 |
| No. transplant recipients (%) | 20 (26) | 7 (35) | 0.442 |
| No. by site of infection (%) | |||
| Pulmonary | 14 (18) | 5 (25) | 0.511 |
| CNS disease | 46 (61) | 12 (60) | 0.966 |
| Bloodstream | 45 (59) | 8 (40) | 0.124 |
| Other site of infection | 12 (16) | 3 (15) | 0.931 |
| No. immunocompetent (%) | 15 (20) | 7 (35) | 0.148 |
| No. with 90-day mortality (%) | 28 (37) | 5 (25) | 0.286 |
| Median days to diagnosis from symptom onset (IQR) | 20.5 (7, 34) | 18 (5, 24) | 0.511 |
| Median days to initiation of antifungals from symptom onset (IQR) | 20 (7, 35) | 18 (5, 24) | 0.561 |
| Median days to initiation of antifungals from admission date (IQR) | 3 (1,7) | 1 (0, 7) | 0.309 |
a
IQR, interquartile range; CNS, central nervous system; CrAg, cryptococcal antigen.